Cargando…

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials

BACKGROUND AND OBJECTIVES: To investigate the potential of plasma neurofilament light (pNfL) as a biomarker of disease progression and treatment response in progressive multiple sclerosis (PMS) with and without acute disease activity. METHODS: A post hoc blinded analysis of pNfL levels in 2 placebo-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leppert, David, Kropshofer, Harald, Häring, Dieter A., Dahlke, Frank, Patil, Ashwini, Meinert, Rolf, Tomic, Davorka, Kappos, Ludwig, Kuhle, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263182/ https://www.ncbi.nlm.nih.gov/pubmed/35379762 http://dx.doi.org/10.1212/WNL.0000000000200258

Ejemplares similares

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
por: Kuhle, Jens, et al.
Publicado: (2019)

Long-term prognostic value of longitudinal measurements of blood neurofilament levels
por: Häring, Dieter A., et al.
Publicado: (2020)

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2018)

Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis
por: Reinert, Marie-Christine, et al.
Publicado: (2020)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Serum neurofilament light chain levels associations with gray matter pathology: a 5‐year longitudinal study
por: Jakimovski, Dejan, et al.
Publicado: (2019)

Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study
por: Tavazzi, Eleonora, et al.
Publicado: (2020)

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Blood neurofilament light chain at the doorstep of clinical application
por: Leppert, David, et al.
Publicado: (2019)

Blood neurofilament light levels segregate treatment effects in multiple sclerosis
por: Delcoigne, Bénédicte, et al.
Publicado: (2020)

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
por: Disanto, Giulio, et al.
Publicado: (2017)

Association of serum neurofilament light with microglial activation in multiple sclerosis
por: Saraste, Maija, et al.
Publicado: (2023)

Serum neurofilament light chain as outcome marker for intensive care unit patients
por: Fisse, Anna Lena, et al.
Publicado: (2020)

Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial
por: Kuhle, Jens, et al.
Publicado: (2023)

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2019)

Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial
por: Bar-Or, Amit, et al.
Publicado: (2022)

Antibodies to neurofilament light as potential biomarkers in multiple sclerosis
por: Puentes, Fabiola, et al.
Publicado: (2021)

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
por: Gaiottino, Johanna, et al.
Publicado: (2013)

White matter lesion location correlates with disability in relapsing multiple sclerosis
por: Gaetano, Laura, et al.
Publicado: (2020)

Serum neurofilament light chains in MS: Association with the Timed Up and Go
por: Allali, Gilles, et al.
Publicado: (2020)

Serum neurofilament light as a biomarker in progressive multiple sclerosis
por: Kapoor, Raju, et al.
Publicado: (2020)

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
por: Harris, Sarah, et al.
Publicado: (2021)

Decreased neurofilament light chain levels in estriol‐treated multiple sclerosis
por: Voskuhl, Rhonda, et al.
Publicado: (2022)

Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parameters
por: Hermesdorf, Marco, et al.
Publicado: (2022)

Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis
por: Maggi, Pietro, et al.
Publicado: (2021)

Development of an age‐adjusted model for blood neurofilament light chain
por: Harp, Christopher, et al.
Publicado: (2022)

Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19
por: Ameres, Markus, et al.
Publicado: (2020)

Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitis
por: Le, Ngoc Dung, et al.
Publicado: (2020)

Factors influencing serum neurofilament light chain levels in normal aging
por: Koini, Marisa, et al.
Publicado: (2021)

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS
por: Kuhle, Jens, et al.
Publicado: (2021)

Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
por: Yeo, Tianrong, et al.
Publicado: (2022)

Evidence of polygenic regulation of the physiological presence of neurofilament light chain in human serum
por: Herrera-Rivero, Marisol, et al.
Publicado: (2023)

Ratio and index of Neurofilament light chain indicate its origin in Guillain‐Barré Syndrome
por: Körtvelyessy, Peter, et al.
Publicado: (2020)

Serum neurofilament light levels in normal aging and their association with morphologic brain changes
por: Khalil, Michael, et al.
Publicado: (2020)

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2021)

Monitoring of radiologic disease activity by serum neurofilaments in MS
por: Uher, Tomas, et al.
Publicado: (2020)

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dr2982pmhq267ctcbqs9tppf1l